Launch Date: 29/08/20
Aprazer Healthcare Launched INLYBEST (Axitinib) which is a medication indicated for the treatment of Advanced Renal Cell Carcinoma and Hepatocellular carcinoma.
Launch Date: 10/08/20
Aprazer Healthcare Launched OCABEST (Obeticholic Acid ) which is a medication indicated for the treatment of Primary Biliary Cirrhosis who have not responded to UDCA treatment.
Launch Date: 13-07-2020
Aprazer Healthcare Launched INDENZA ( ENZULATAMIDE ) which is a medication indicated for the treatment of castration-resistant prostate cancer (CRPC) and metastatic castration-sensitive prostate cancer (mCSPC) .
Launch Date: 24-06-2020
Aprazer Healthcare Launched Rifaxigem ( Rifaximin) which is a medication indicated for the treatment of IBS with Diarrhea and Hepatic Encephalopathy.
Launch Date: 03-06-2020
Aprazer Healthcare Launched DASAKAST (Dasatinib ) which is a medication used to treat newly diagnosed adults Philadelphia Chromosome -Positive( Ph+ ) Chronic Myeloid Leukemia in Chronic Phase, Advanced Chronic Leukemia & Acute Lymphoblastic Leukemia.
Aprazer Healthcare Launched ABIRAKAST (Abiraterone acetate ) which is a medication used to treat prostate cancer specifically it is used together with corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC)
Aprazer Healthcare Launched SORAFEKAST (Sorafenib Tablets ) is a kinase inhibitor drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), FLT3-ITD positive AML and radioactive iodine resistant advanced thyroid carcinoma.
Launch Date: 21-12-2019
Aprazer Healthcare Launched IMATIKAST (IMATINIB ) which is a medication used to treat
• Myelodysplastic/Myeloproliferative Diseases.
• Hypereosinophilic Syndrome and/or Chronic Eosinophilic Leukemia.
• Chronic Myeloid Leukemia Philadelphia-Chromosome-positive.
• Dermatofibrosarcoma Protuberans.
• Mastocytosis.
• Gastrointestinal Stromal Tumors.
Launch Date: 06-12-2019
Aprazer Healthcare Launched HEPAKAST containing l-leucine; l – isoleucine: l-valine. HEPAKAST is a Health Supplement indicated in Hepatic Encephalopathy & other Liver Diseases.
Aprazer Healthcare Launched under its brand Sofokast Plus, the generic fixed dose combination of Sofosbuvir 400 mg and Daclatasvir 60mg Tablet, for the treatment of patients with chronic hepatitis C virus (HCV) infection.
